Health
ASTRAZENECA SECURES LICENSE EXTENSION AND EARLY NHS ENGLAND ACCESS TO TAGRISSOTM (osimertinib) FOR PATIENTS WITH COMPLETELY RESECTED EARLY-STAGE – PharmiWeb.com
ASTRAZENECA SECURES LICENSE EXTENSION AND EARLY NHS ENGLAND ACCESS TO TAGRISSOTM (osimertinib) FOR PATIENTS WITH COMPLETELY RESECTED EARLY-STAGE EGFR MUTATION-POSITIVE…
ASTRAZENECA SECURES LICENSE EXTENSION AND EARLY NHS ENGLAND ACCESS TO TAGRISSOTM (osimertinib) FOR PATIENTS WITH COMPLETELY RESECTED EARLY-STAGE EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER
- This is the first authorisation to be issued by the MHRA under Project Orbis.1
- AstraZeneca, NHS England and NICE have reached an agreement to enable early access to osimertinib for patients with this type of cancer, while NICE undertakes its appraisal.
- Patients with early-stage lung cancer are treated…
Continue Reading
-
General23 hours agoDairy farmers devastated by floods across parts of New South Wales
-
Noosa News20 hours agoBrisbane’s Triffid forces redesign of $1.5 billion tower project
-
Noosa News23 hours agoMan dies in Gold Coast after rolling trailer pins him to lamp-post
-
General20 hours agoSussan Ley’s office says Bridget McKenzie made false claims about cabinet solidarity